anushree gulvady-hayes, PhD

Anushree Gulvady-Hayes, PhD
Patent Agent
anushree.gulvadyhayes@mcneilliplaw.com
O: 617.430.4740 ext. 894
vCard |  LinkedIn
McNeill PLLC
245 First Street
18th Floor
Cambridge, MA 02142*

Leveraging life science expertise and legal skillsets to develop valuable patent portfolios

Anushree’s practice focuses on the preparation, prosecution, and portfolio strategy of domestic and international patent applications. Her patent experience spans various fields, including antibody technologies, gene therapies (CRISPR/Cas, TALEs, ZFPs), cell therapies, engineered cells, epigenomics, genomics, recombinant nucleic acids and arrays, cancer, immunology, and infectious diseases.

Before joining McNeill PLLC, Anushree spent four years at Morrison & Foerster as a scientific analyst and a patent agent, specializing in drafting and prosecuting US and international applications.

Anushree earned her PhD, with distinction, in anatomy and cell biology from the SUNY Upstate Medical University, where she worked on cell migration and metastasis. As a postdoctoral researcher at the Dana-Farber Cancer Institute, a principal affiliate of Harvard Medical School, she focused on identifying novel metastatic signatures for breast cancer. Anushree was also a business development fellow at the Office of Technology Development at Harvard University, where she developed commercialization strategies for biotechnologies. Anushree co-chaired and organized multiple patent law lecture series with Morrison & Foerster and Finnegan, Henderson, Farabow, Garrett & Dunner for the Harvard Biotechnology Club and the Boston community.

Select Publications

TBCRC 039: A Phase II Study of Preoperative Ruxolitinib with or without Paclitaxel for Rriple-negative Inflammatory Breast Cancer,” Breast Cancer Research 26(1):20, 2024 (coauthor).

Heterogeneity and Transcriptional Drivers of Triple-negative Breast Cancer,” Cell Reports 42(12):113564, 2023 (coauthor).

Breast Cancer Prevention by Short-term Inhibition of TGFβ Signaling,” Nature Communications 13:7558, 2022 (coauthor).

Acquired Resistance to Combined BET and CDK4/6 Inhibition in Triple-negative Breast Cancer,” Nature Communications 11:2350, 2020 (coauthor).

Hic-5 Regulates Src-induced Invadopodia Rosette Formation and Organization,” Molecular Biology of the Cell 30(11):1298-1313, 2019 (coauthor).

Paxillin-dependent Regulation of Apical-basal Polarity in Mammary Gland Morphogenesis,” Development 146(9): dev174367, 2019 (coauthor).

Hic-5 Expression is a Major Indicator of Cancer Cell Morphology, Migration, and Plasticity in Three-dimensional Matrices,” Molecular Biology of the Cell 29(13):1704-1717, 2018 (coauthor).

 

 

Admissions

US Patent and Trademark Office

 

*Not admitted in MA

 

Education

Syracuse University College of Law

JD, expected graduation 2027

 

SUNY Upstate Medical University

PhD, Anatomy & Cell Biology, 2018

 

University of Mumbai

MS, Microbiology, 2011

 

University of Mumbai

BS, Microbiology, 2009